Antibody (Suitable for clinical applications)
Sample Type: FFPE Patient Samples.
Tested Applications: IHC. Approved for In Vitro Diagnostic Procedures on FFPE tissues. For tissue collection recommendations, please see datasheet sent with product.
|Recommended Dilution (Conc)
||Only Available as Predilute
||EDTA Buffer pH 8.0
||30 min at Room Temperature
Prior to use, inspect vial for the presence of any precipitate or other unusual physical properties. These can indicate that the antibody has degraded and is no longer suitable for patient samples. Please run positive and negative controls simultaneously with all patient samples to account and control for errors in laboratory procedure. Use of methods or materials not recommended by enQuire Bio including change to dilution range and detection system should be routinely validated by the user.
Anti-Pax-8 Antibody Clone: 4H7B3
Host and Isotype: Mouse IgG1
Recommended Positive Control Sample: Normal kidney, renal cell, or serous ovarian carcinomas
Cellular Localization of Antibody 4H7B3 Staining: Nuclear
Buffer and Stabilizer: PBS with 1% BSA and 0.05% NaN3
Lot specific. Plese contact tech support
Storage Conditions: This antibody should be stored refrigerated (2-8°C). This product should not be used past the expiration date printed on the vial.
Pax-8 Information for Pathologists
Also called Paired box 8. Discovered in 1990 (Development 1990;110:643). Paired domains are composed of two helix-turn-helix subdomains. The N-terminal subdomain and the C-terminal subdomain, both of which can bind DNA independently (Cell 1995;80:639). Structurally similar to PAX2 and PAX5.
Common Uses By Pathologists:
Differentiate PAX8+ primary or metastatic tumors (kidney, MÃ¼llerian [but not mucinous, Am J Surg Pathol 2011;35:1837], thymic, thyroid) from PAX8- tumors (adrenal, breast, GI [most], lung, prostate, Am J Surg Pathol 2011;35:816). Differentiate prostatic mesonephric remnant hyperplasia (PAX8+) from prostatic adenocarcinoma (PAX8-, Am J Surg Pathol 2011;35:1054). Differentiate metastatic clear cell renal cell carcinoma (PAX2+ or PAX8+ / inhibinA neg) from hemangioblastoma (PAX2-, PAX8-, inhibin A+, Am J Surg Pathol 2011;35:262). Differentiate endosalpingiosis in axillary lymph nodes (PAX8+ / WT1+) from metastatic breast carcinoma (PAX8-, WT1-, Am J Surg Pathol 2010;34:1211). Differentiate renal collecting duct carcinoma (PAX8+ / p63-) from urothelial carcinoma of upper urinary tract (PAX8- / p63+, Am J Surg Pathol 2010;34:965).
Limitations and Warranty
This antibody is manufactured in accordance with clinical good manufacturing practices in an ISO13485:2016 certified production facility. It is intended for multiple uses including in vitro diagnostic use and research use only applications. Please see vial label for expiration date. We strive to always deliver antibodies with a shelf life of at least two years.